RxDoctor Payments Data

Gustavo Forteza, MD

General Practice · Hialeah Gardens, FLNPI 1770569196

Payments from drug & device makers

$2,025in general payments, 2019–2025

Across 102 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$396
  • Sunovion Pharmaceuticals Inc.$293
  • AbbVie$274
  • Novartis$129
  • Pfizer$127
  • Novo Nordisk$119
  • plus $687 from 12 others

What the payments were for

  • Food & beverage$2,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,025 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$42,961
Medicare patients
41
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol122$81,273
EliquisApixaban109$71,071
OzempicSemaglutide32$39,646
RestasisCyclosporine56$37,188
XareltoRivaroxaban55$35,743
EntrestoSacubitril/Valsartan36$33,058
MounjaroTirzepatide25$26,864
JanuviaSitagliptin Phosphate36$21,935
LinzessLinaclotide33$19,869
Synjardy XrEmpagliflozin/Metformin Hcl27$14,978
JardianceEmpagliflozin19$14,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,779
VascepaIcosapent Ethyl27$13,097
JanumetSitagliptin Phos/Metformin Hcl16$12,068
SynjardyEmpagliflozin/Metformin Hcl15$10,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$396$85,088140 claims
PfizerEliquis$127$71,071109 claims
AbbVieRestasis, Linzess, Lumigan$274$63,470115 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$118$39,98161 claims
Novo NordiskOzempic$119$39,64632 claims
Johnson & JohnsonXarelto$115$35,74355 claims
MerckJanuvia, Janumet$20$34,00352 claims
NovartisEntresto$129$33,05836 claims
Lilly USA, LLCMounjaro$15$26,86425 claims
GSKTrelegy Ellipta, Breo Ellipta$35$22,14741 claims
Smith+NephewSantyl$62$5,70017 claims
Astellas Pharma US IncMyrbetriq$86$5,28013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Hialeah Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →